|Videos|March 15, 2022
Decentralized Clinical Trials in a Covid-19 Landscape
Author(s)YPrime
YPrime President, Mark Maietta, discusses the future of decentralized clinical trials following Covid-19. Adaptations will need to be made as DCT is here to stay.
• Regulatory has begun to investigate new methods and technologies for the clinical trial process.
• Clinical trials will have more decentralized components going forward.
• The key is matching a protocol and patient with the new components of DCT.
Related Content
Trending on Applied Clinical Trials Online
1
AI-Driven Clinical Trial Recruitment and Design
2
Agentic RTSM and the Push to Compress Clinical Trial Startup: Q&A with Robert Hummel, Suvoda
3
Why Clinical Trials Need an Execution Architecture Before AI Can Deliver: Q&A with Abraham Gutman, AG Mednet
4
How RBQM Needs to Evolve for a Real-Time Oversight World
5